The study objective was to determine the presence of MMP-7 in cancer tissue in correlation with its serum level in patients diagnosed with colorectal cancer (CRC). In 45 patients with CRC, MMP-7 expression was assessed immunohistochemically on FFPE slides in tumours (N = 37) and in the corresponding surgical margin sample. MMP-7 serum level was measured preoperatively. The expression of MMP-7 in cancer tissue was much stronger as compared to the normal intestinal mucosa. Also the level of MMP-7 in the serum of CRC patients was higher than in healthy subjects (N = 24) (p < 0.01). The tumour located in the colon showed higher expression of MMP-7 than CRCs located in the rectum (p < 0.05), whereas the higher MMP-7 serum level showed correlation with older age (p = 0.005), tumour size less than 5 cm (p < 0.05), higher Dukes' stage (p < 0.05) and distant metastases (p < 0.05). The increased serum level of MMP-7 in CRC patients may indicate the presence of distant metastases.
Introduction
Colorectal cancer (CRC) is the third most common malignancy worldwide in men and women [1] . Poland belongs to Central European countries with moderate morbidity rates, CRC is mainly a disease of developed Western countries [2] . CRC is the fourth leading cause of death, with prognosis indicating a growing trend [3] . The diagnosis is usually late and 5-year survival rate ranges from 90% for early cancers, 70% for regional, to 10% for distant metastatic cancers. Therefore, there are studies for new and effective markers that could detect CRC and for therapeutic purposes [4] .
Carcinogenesis in the large intestine is a complex, multi-stage process leading to excessive tissue proliferation that cannot be controlled by natural mechanisms due to predominance of cell proliferation over cell death. However, local neoplastic growth would not be possible without reconstruction of the extracellular matrix (ECM). Stromal degradation and looseness also allow migration of cancer cells and thus their dissemination, vascular invasion and formation of distant metastases. The reconstruction of the ECM involves a variety of digestive enzymes [5, 6 ]. However, a major role can be ascribed to me- www.fhc.viamedica.pl talloproteinases, which are intensively investigated in carcinogenic processes.
One of the most important metalloproteinases is MMP-7 due to its low molecular mass (28 kDa) and unique structure; it is also called matrilysin-1 or PUMP-1 [7] . Physiologically, MMP-7 is found in ductal and glandular epithelium of many tissues, also in monocytes or mesangial cells [8] [9] [10] [11] . On the other hand, its overexpression has been detected in various neoplastic lesions, including lung, prostate, stomach and colon cancer [12] [13] [14] [15] . Active matrilysin-1 shows a proteolytic activity on the ECM components, such as collagen, elastin, laminin, proteoglycans, fibronectin and casein [9] . It is also able to activate other metalloproteinases (MMP-2 and MMP-9) affecting the ECM, which promotes invasion of cancer cells [16] [17] [18] . Apart from the digestion of the stroma, MMP-7 also takes part in other processes involved in the carcinogenesis through breakdown of the cell surface protein [19] . In this way, the enzyme can induce proliferation [19] [20] [21] , and regulate apoptosis [22, 23] , angiogenesis [24] and escape of cancer cells against the immune system [25] .
The knowledge of the mechanisms that regulate carcinogenesis could help to predict the advancement of neoplastic disease and, eventually, inhibit its progression. Therefore, we decided to detect the presence of MMP-7 in cancer tissue in correlation with its serum level in CRC patients and to analyse this protein as a potential marker in clinical practice.
Material and methods
Patients. The study was carried out on a group of 45 patients with CRC (30 men and 15 women aged 34-86 years, mean 66.8 ± 11.8, median 66) treated in the 2nd Department of General and Gastroenterological Surgery, Medical University of Bialystok, Poland, in the years 2007-2009. Colorectal cancers were diagnosed histopathologically as the adenocarcinoma type without the mucinous component in 40/45 patients and as the mucinous type in 5/45 patients. Histologically, the tumours were identified as moderately-(42/45 patients) or poorly-differentiated carcinomas (3/45 patients). According to TNM classification, in one case tumour infiltration was limited to the submucosa (pT1), in 4 cases the muscular layer was invaded (pT2) and in as many as 40 cases the subserosa was involved (pT3). In 25/45 patients, there was local lymph node involvement and in 18/45 distant metastases were found, mainly in the liver, pancreas, lungs, kidneys, ovaries and uterine body. The surgical interventions were not preceded by chemotherapy or radiotherapy.
The blood (5 mL) of 45 colorectal cancer patients was drawn for clot prior to surgery. Blood serum was stored frozen at -80°C immediately after separation by centrifugation until the assay was performed.
The control group consisted of 24 healthy subjects (13 men and 11 women aged 45-75 years, mean 55.7 ± 7.3, median 54.5). The blood was collected from control patients before colorectal cancer screening test -colonoscopy.
The study was approved by the local Bioethics Committee. Each patient gave written informed consent for participation in the study.
Immunohistochemistry. The expression of MMP-7 protein was determined in cancer tissue and normal tissue of the surgical margin of CRC patients (glandular and surface epithelium) by immunohistochemistry. The tissue material was obtained only from 37 patients. The study used archival material consisting of paraffin-embedded colorectal cancer tissues. The control group included samples of healthy mucosa of the colon, collected from the resected unchanged intestinal fragments of the same patients (N = 37). Formalin-fixed and paraffin-embedded tissue specimens were cut with a microtome into 4 µm sections and mounted on silinized glass slides. The sections were deparaffinized in xylene and hydrated in alcohols. The antigen retrieval was not performed. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 min. Protein blocking was done with a serum-free protein blocker (Novocastra, UK) to reduce non-specific binding of primary and secondary antibodies. Next, they were incubated with murine monoclonal anti-human MMP-7 antibody (clone: 111433, R&D Systems, UK) in 1:500 dilution for 60 min. at room temperature. The primary antibody was specific for human pro-and active forms of MMP-7. The streptavidin-biotin reaction (Biotinylated Secondary Antibody, Streptavidin-HRP, Novocastra, UK) was followed according to manufacturer's protocol by visualization of the antigen-antibody complex using chromogen 3,3-diaminobenzidine (DAB, Novocastra, UK). Nuclei were counterstained with hematoxylin.
Positive reaction for MMP-7 was observed in the cytoplasm of normal mucosa and in cancer cells. Positive and negative controls were performed according to the producer's protocol (Novocastra, UK).
The expression of MMP-7 protein was assessed semiquantitatively based on staining intensity, which was defined depending on visualization of the reaction at the respective microscopic magnifications. The expression was defined as strong when the reaction was visible at × 40 total magnification, moderate -at × 100, poor -at × 200, lacking -when not visible at × 200. Since there were only 4 cases with lacking or poor reaction, they were treated as one group for statistical purposes. www.fhc.viamedica.pl the specimens were assayed twice in duplicate. The MMP-7 Quantikine ELISA kit detected both pro-and active forms of recombinant and normal human MMP-7. The results were presented in nanograms per millilitre.
Enzyme-linked immunoabsorbent assays (ELISA
Statistics. Statistical analysis was based on STATISTICA 8.0 program (Statsoft, Cracow, Poland). Statistical analysis was conducted using Student's t-test. The data distribution was normal according to Shapiro-Wilk W-test. The Mann-Whitney U-test was used to compare the two groups. Spearman's correlation coefficient test was applied to find correlations of serum protein level with clinicopathological factors and morphological parameters of blood. The value of p < 0.05 was considered statistically significant. Missing data were removed in pairs. Additionally, the area under the ROC curve (AUC) was assessed using MedCalc statistical software (MedCalc Software, Ostend, Belgium).
Results

Immunohistochemical expression of MMP-7 in colorectal cancer
In normal mucosa membrane of the resected fragment of the large intestine, the expression of MMP-7 was either lacking or poor to moderate, and irregularly distributed in glands (Figure 1 A) . In the colorectal cancer samples, the positive reaction was observed in the cytoplasm of cancer cells and identified as negative or poor in 4 patients, moderate in 18 and strong in 15 cases (Figure 1 B, C, D) . The statistical analysis showed no significant correlations of MMP-7 expression in cancer tissue with gender and age of patients, tumour grade, tumour stage (pT), Dukes' classification, lymph node involvement or distant metastases. A statistically significant correlation was found between tumour location in the colon and high expression of MMP-7 in cancer tissue. In rectal cancers, moderate expression of MMP-7 was predominant (p < 0.05; r = -0.355) ( Table 1) .
Serum MMP-7 levels of colorectal cancer and control patients
The serum concentration of MMP-7 in colorectal cancer patients ranged between 4.32 and 12.93 ng/mL (7.45 ± 1.88 ng/mL, mean and SD; N = 45), and was significantly higher than in healthy subjects (6.31 ± ± 0.91 ng/mL, range 4.94-8.26, N = 24) (p < 0.01). The ROC curve showed that the cut-off point for MMP-7 was at the level of 6.88 ng/mL (sensitivity 58.3% and specificity 87.5%). The area under the ROC curve for MMP-7 level was 0.710, which indicates mode- 
Correlations between serum MMP-7 levels and clinicopathological parameters in colorectal cancer patients
The serum level of MMP-7 in CRC patients over 60 years of age (mean 73.2 ± 7.4, median 74) was significantly higher than in the group of younger patients (> 60 years old, mean 52.9 ± 6.2, median 54) ( Table 2) . Tumours > 5 cm in diameter were found to correlate with lower serum concentration of MMP-7, whereas those < 5 cm in diameter had higher matrilysin-1 level (Table 2 ). Moreover, the increased level of MMP-7 correlated with higher stage in Duke's classification (Table 2) . A positive correlation was also observed between the presence of distant metastases and higher serum MMP-7 level in CRC patients (Table 2) . No statistically significant differences were noted between the serum level of MMP-7 and other clinicopathological parameters. (Table 2) .
Correlations between serum MMP-7 levels and blood morphology parameters in colorectal cancer patients
The statistical analysis revealed a negative correlation between serum level of MMP-7 and serum glucose concentration in CRC patients (p < 0.01) (Table 3) . However, any significant correlation was found between serum MMP-7 concentration and other parameters.
Discussion
The current study confirmed the observations of other authors that MMP-7 expression in colorectal cancer tissues is markedly higher than in normal intestinal mucosa, which proves the involvement of this metalloproteinase in CRC growth [26] [27] [28] [29] [30] . Also the finding of enhanced MMP-7 mRNA confirmed the involvement [11, 31, 32] . The statistical analysis showed only a stronger relationship of MMP-7 overexpression with tumours located in the colon as compared to those in the rectum. However, we revealed no significant correlations between MMP-7 expression in tumour cells and CRC advancement, similarly to Gomes et al. [26] , who used antibody that detected both pro-and active forms of MMP-7. However, investigations done by Wang et al. [33] proved the correlation of positive MMP-7 expression with tumour infiltration depth in the intestinal wall and with distant metastases. Ogawa et al. [34] noted that MMP-7 expression in lymphatic vessels is a useful parameter in predicting CRC metastases to the liver. They also showed that the assessment of matrilysin expression can help prognosticate the course of the disease. Koskensalo et al. [28] revealed a link between high MMP-7 reaction in cancer and worse prognosis during a 5-year follow-up. Also research data on mRNA MMP-7 expression are [35] found a correlation of MMP-7 mRNA overexpression with advanced Dukes' stage and the presence of metastases to the liver. Our immunohistochemical findings do not seem to indicate that MMP-7 is a CRC stage marker. However, according to the results, the assessment of its preoperative serum level can be such a marker. We demonstrated a correlation of the increased serum level of MMP-7 with higher Dukes' stage and with distant metastases. Also Maurel et al. [36] observed elevated serum levels of MMP-7 in patients with advanced CRC as compared to non-metastatic CRC. Moreover, they showed MMP-7 to be an independent prognostic factor for survival in patients with advanced CRC. On the other hand, Martinez-Fernandez et al. [37] , found not only the correlation between increased serum level of MMP-7 and worse prognosis, but also revealed that MMP-7 predicts recurrence in curatively resected CRC patients. Additionally, similarly to our observations, they noted high serum level of MMP-7 in older CRC patients.
We divided the study group of colorectal cancers into < 5 cm and > 5 cm tumours. Interestingly, we observed a correlation between the increased serum level of MMP-7 in CRC patients and tumours < 5 cm in diameter. However, literature data do not confirm this correlation.
We also examined correlations between serum levels of MMP-7 in CRC patients with other blood parameters. In our study, a rise in the level of MMP-7 was associated with decreased blood glucose levels. Maurel et al. [36] showed a relationship between high serum level of MMP-7 in CRC patients and elevated parameters, such as LDH, ALP and CEA. Perhaps, MMP-7 affects these factors through involvement in some unknown mechanisms. We observed increased expression and level of MMP-7 both in immunohistochemical investigations and in ELISA, as compared to the control group. Although we used the antibody detecting pro-and active forms of MMP-7 in both methods, we found no correlation between the immunohistochemical expression of MMP-7 in cancer tissue and its blood serum level in CRC patients. Perhaps, the ratio of pro-and active forms of MMP-7 differs between tissue and serum in CRC patients, one of them having prognostic advantage over the other. Future investigations using specific antibodies or assessment of MMP-7 activity with zymographic method might help elucidate this phenomenon. Nevertheless, MMP-7 should be considered as an important factor in the carcinogenic process, especially, as a marker of the disease advancement that can be determined with a simple noninvasive ELISA method. The current study seems to confirm and extend earlier analyses of other authors concerning MMP-7 expression in CRC, indicating possible use of MMP-7 as a prognostic marker of CRC.
